Vascular calcification and QT interval in incident hemodialysis patients

In the article Vascular calcification and QT interval in incident hemodialysis patients, by Di Iorio B.R. et al, published in J Nephrol 2009; 22(6): 694-698, the abstract was misprinted. We hereby reprint the correct version: "This study proposes to evaluate the impact of different phosphate binders on the slowing of cardiovascular calcification and QT dispersion in incident hemodialysis patients with a follow-up of 36 months. This is to be a randomized, multicenter, perspective, interventional study. Inclusion criteria are age over 18 years and being an incident patient on hemodialysis. Exclusion criteria are congenital prolongation of QT segment syndrome, QT-c >440 ms, bradycardia <50 beats per minute, symptomatic arrhythmia or any other significant heart problems; electrolyte imbalances (especially hypokalemia, hypomagnesemia or hypocalcemia); abnormal liver function tests and hypothyroidism. An informed consent will be taken at study entry. The patients will be randomized to 2 cohorts: 180 patients in the sevelamer group and 180 patients in the calcium-binder phosphate group. Related vascular calcification mortality is the principal end point and will be evaluated at 36 months."